Next Phase Newsletter

A private equity firm headquartered in Asia has invested over $8.5B. The life science investment team invests in breakthrough innovations that potentially addresses unmet medical need. The firm has a dedicated life science investment team and invests in early and venture stage companies. For life science, the firm invests within $10M USD per round. 
 
The firm invests opportunistically in the life sciences. The firm seeks an opportunity to invest in innovative therapeutics, medical devices, digital health, diagnostics, and healthcare services that are in discovery/development stage. The firm prioritizes new IP/NCE and modality over repurposed or reformulated products. 

The firm generally requires a seat on the board of directors or observers. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   
 

A digital health investment company focuses on the digital health space and invest in companies that use data and intelligence derived from data to solve important healthcare problems. The firm’s investments range dependent on the opportunity, and focuses mainly on Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to invest globally. 
 
The firm focuses on digital health technologies and solutions that aim to improve the quality and the delivery of patient care. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data. The firm is also interested in technology with machine-learning applications. The firm is not interested in pure EMR or hospital IT systems. Based on all the criteria, the firm is indication agnostic. 
 
The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A US-based VC firm is made up of ex-startup founders/engineers. The firm invests in pre-seed and seed companies, and may make a follow up investment in companies for Series A as well. The firm’s typical check size is between $50K – $300K. The firm is investing from their 2nd fund and is looking to invest in 8 companies per year with this current fund. 
 
The firm focuses on technology investments focused on AI. Within the healthcare space, areas of interest include companies focused on human enhancement, brain longevity, and prevention. The firm invests in companies in the in-development and pre-clinical stages. The firm does not have any prototype requirements and has made prior investments as early as products still being concepts. Previous investments have included a company focused on AI enabled diagnostics. 
 
The firm invests primarily within the USA but is open to investing in other areas if the opportunity fits. The firm will lead or co-invest, and will take a board seat if leading in later rounds. The firm typically leads in pre-seed rounds as they are often the first investment check for a company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An early-stage venture capital firm founded 2020. The firm focuses on science-led, IP-driven, and/or technically defensible companies in Pre-Seed and Seed stages. The firm has a core focus on biotechnology, life science, and wellness companies. Initial check sizes range from $100k-250k USD and often is the 1st check in to companies. Currently, the firm is only looking to invest in the U.S. and Canada. 
 
The firm is broadly interested in the following sectors: precision medicine & healthcare, longevity, tech-bio, neurotechnology, human augmentation, and wellness. More specifically, these areas include, but are not limited to: cell/gene therapy, precision and personalized medicine, epigenetic reprogramming, organoid technology leading to enhanced therapeutic benefit, RNA therapeutics, quantified self / functional health / wellness / continuous monitoring, longevity, microbiome health, psychedelics, science-backed mental health, autoimmune disease management, women’s health and wellness, food as medicine, infant health and wellness, food security, synbio, reproductive aging and family planning, and early disease detection. The firm is open to companies at the in-development and pre-clinical stages. 
 
The firm doesn’t require founders to be fulltime when establishing a relationship, but when getting investments, founder should be or on track to be fulltime. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A Chinese specialty pharmaceutical company with offices in US and China focuses on product development and sales and marketing in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory system. The firm is interested in forming partnerships with biopharmaceutical companies that are interested in entering the Chinese market. The firm is flexible in terms of partnering models, which includes in-licensing, co-development, exclusive distribution, joint venture, and product acquisition. The firm is actively seeking products from the US and Europe. 
 
The firm has a primary focus in seeking products in Phase II/III or already been approved or launched in US or EU and in Surgery, Pediatric, Respiratory, ICU, Oncology and Nephrology areas. However, the firm will also look into the products in Cardiovascular, Clinical nutrition and Pain management, but these are not the current priority for now. The firm is equally interested in other areas with unmet medical needs in China (such as CNS, GI, Nephrology, etc). The firm will consider both small molecules and biologics. The firm is most interested in NCE or NCE-like molecules. The firm will only consider biosimilar or generics if there are no similar products or very few players with identical chemical/biological structure in China.  In terms of phase of development, the firm will consider marketed and early-late clinical stage products for the five listed areas above. For other therapeutic areas, the firm is looking for assets that have obtained regulatory approval in the US or Europe markets. 
 
The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A family office located in the US makes approximately 2 to 3 equity investments per year into healthcare companies located in the United States. The firm does not have an average investment size as it depends on the opportunity, however – the firm looks to take a control seat when doing so as they are a value added investor. 
 
The firm is interested in services, HCIT, diagnostics, medical devices, and auxiliary services. The firm is very opportunistic within these areas and they are agnostic with regard to indication areas. The firm looks for growth stage companies located in the United States that are generating profits or close to doing so. The firm is not interested in long term deals and prefers companies with 48 months of an exit. 
 
The firm has no explicit management team requirements as the firm is a value-added investor and takes an active role in its portfolio companies. The firm requests a board seat and provides its portfolio companies with experienced talent to help improve operations. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An impact venture fund focuses on quality of life/healthcare, climate, and education, having specialized teams for each vertical. The firm is currently investing from their first fund, allocating €1M EUR for initial checks with flexibility to make follow-on investments. The firm invests in Seed rounds but can enter earlier or later. 80% of investments are made in Spain with the other 20% made across Europe. 
 
In terms of healthcare, the firm is technology agnostic and invests in solutions that help improve the quality of life for vulnerable populations: the elderly, people with chronic diseases, and people with mental or physical disabilities. For digital health companies, the firm would like to see product-market fit. 
 
The firm can act as a lead investor and join syndicates. The firm requests to take a board seat as they like to be active investors. The firm would like to see committed and diverse management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.